This page shows the latest iGlarLixi news and features for those working in and with pharma, biotech and healthcare.
In almost a mirror image, Sanofi's Soliqua (variously known as iGlarLixi and LixiLan) combines top-selling basal insulin Lantus (insulin glargine) – albeit now facing biosimilar competition in some markets - and
Sanofi is highlighting new data for its IGlarLixi combination drug for diabetes showing it is more effective at controlling mealtime blood glucose than its Lantus blockbuster. ... The FDA scuppered those plans last month by announcing a delay of up to
The FDA has asked for more information on Sanofi and Zealand Pharma's IGlarLixi combination drug for diabetes, giving a rival drug from Novo Nordisk a chance to be first to ... The FDA is due to deliver a verdict on Xultophy next month, with a decision
Sanofi's combination insulin/GLP-1 agonist drug iGlarLixi (formerly LixiLan) has met objectives in two phase III trials, setting up a showdown in the diabetes market. ... The positive data comes as iGlarLixi approaches an FDA decision on approval - due
The FDA panel voted 12 to 2 in favour of approval for iGlarLixi - a combination of insulin glargine and GLP-1 agonist lixisenatide - as an adjunct to diet and exercise to ... iGlarLixi and other new drugs such as longer-acting Lantus follow-up Toujeo are
The committee's decision could also give Novo a boost over its diabetes rival Sanofi, whose similar combination of iGlarLixi (which brings together Lantus and Lyxumia) is due to be reviewed
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...